Dr. Galal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 Trent Dr
Durham, NC 27710Phone+1 919-684-2255
Education & Training
- Ain Shams University Faculty of MedicineClass of 1985
Certifications & Licensure
- NJ State Medical License 2024 - 2025
- NC State Medical License 2017 - 2024
- SD State Medical License Active through 2018
Clinical Trials
- A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Roles: Principal Investigator
- DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Roles: Contact
Publications & Presentations
PubMed
- Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder
Blood Advances. 2025-01-14 - 2 citationsImpact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10 - 1 citationsOutcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker
Journal of Clinical Oncology. 2024-10-17
Press Mentions
- Leukemia Cure We’re Waiting for? Patient Cancer-Free for 11 Years After Innovative TreatmentJune 11th, 2022
- Leukemia Cure? Patient Still Cancer-Free 11 Years After Innovative TreatmentJune 9th, 2022
- The World Needs a Breakthrough YearJune 7th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: